title: Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease.
abstract: The retinoblastoma (Rb)-E2F transcriptional regulatory pathway plays a major role in cell-cycle regulation, but its role in invasion and metastasis is less well understood. We find that many genes involved in the invasion of cancer cells, such as matrix metalloproteinases (MMP), have potential E2F-binding sites in their promoters. E2F-binding sites were predicted on all 23 human MMP gene promoters, many of which harbored multiple E2F-binding sites. Studies presented here show that MMP genes such as MMP9, MMP14, and MMP15 which are overexpressed in non-small cell lung cancer, have multiple E2F-binding sites and are regulated by the Rb-E2F pathway. Chromatin immunoprecipitation assays showed the association of E2F1 with the MMP9, MMP14, and MMP15 promoters, and transient transfection experiments showed that these promoters are E2F responsive. Correspondingly, depletion of E2F family members by RNA interference techniques reduced the expression of these genes with a corresponding reduction in collagen degradation activity. Furthermore, activating Rb by inhibiting the interaction of Raf-1 with Rb by using the Rb-Raf-1 disruptor RRD-251 was sufficient to inhibit MMP transcription. This led to reduced invasion and migration of cancer cells in vitro and metastatic foci development in a tail vein lung metastasis model in mice. These results suggest that E2F transcription factors may play a role in promoting metastasis through regulation of MMP genes and that targeting the Rb-Raf-1 interaction is a promising approach for the treatment of metastatic disease.
authors.affiliation: Department of Tumor Biology, University of South Florida, Tampa, Florida, USA.
authors.forename: Jackie L
authors.initials: JL
authors.lastname: Johnson
authors.forename: Smitha
authors.initials: S
authors.lastname: Pillai
authors.forename: Danielle
authors.initials: D
authors.lastname: Pernazza
authors.forename: Saïd M
authors.initials: SM
authors.lastname: Sebti
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Lawrence
authors.forename: Srikumar P
authors.initials: SP
authors.lastname: Chellappan
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D050684:E2F Transcription Factors / Q000235:genetics* / Q000378:metabolism; D057075:Enzyme Assays / Q000379:methods; D005260:Female; D005780:Gelatin / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D020782:Matrix Metalloproteinases / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D009362:Neoplasm Metastasis; D049488:Phosphatidylethanolamine Binding Protein / Q000378:metabolism*; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D014162:Transfection
chemical_list: D050684:E2F Transcription Factors; D049488:Phosphatidylethanolamine Binding Protein; D016160:Retinoblastoma Protein; D005780:Gelatin; D020782:Matrix Metalloproteinases
references.citation: J Pathol. 1999 Nov;189(3):300-8
references.pmid: 10547590
references.citation: Cancer Res. 1987 Jun 15;47(12):3239-45
references.pmid: 2438036
references.citation: Cancer Res. 2008 May 15;68(10):3810-8
references.pmid: 18483265
references.citation: Arch Biochem Biophys. 2002 Mar 15;399(2):212-24
references.pmid: 11888208
references.citation: Nat Rev Cancer. 2009 Nov;9(11):785-97
references.pmid: 19851314
references.citation: Eur J Cancer. 2003 Sep;39(13):1948-56
references.pmid: 12932675
references.citation: Cancer Res. 2008 Jul 1;68(13):5104-12
references.pmid: 18593909
references.citation: Nucleic Acids Res. 2002 Apr 15;30(8):1859-67
references.pmid: 11937641
references.citation: Oncogene. 2002 Feb 21;21(9):1359-69
references.pmid: 11857079
references.citation: Mol Cancer Res. 2003 Mar;1(5):333-45
references.pmid: 12651907
references.citation: Genes Dev. 1992 Feb;6(2):177-85
references.pmid: 1531329
references.citation: Eur J Cancer. 2000 Aug;36(13 Spec No):1621-30
references.pmid: 10959048
references.citation: Gene. 2000 Jan 25;242(1-2):75-86
references.pmid: 10721699
references.citation: EMBO J. 2004 Dec 8;23(24):4709-16
references.pmid: 15538380
references.citation: Mol Cell Biol. 2004 Nov;24(21):9527-41
references.pmid: 15485920
references.citation: Int J Biochem Cell Biol. 2008;40(6-7):1362-78
references.pmid: 18258475
references.citation: Bioessays. 1996 Jan;18(1):55-62
references.pmid: 8593164
references.citation: Cancer Res. 2003 Sep 1;63(17):5224-9
references.pmid: 14500349
references.citation: Mol Cell Biol. 1996 Mar;16(3):1047-57
references.pmid: 8622649
references.citation: Semin Oncol. 2002 Feb;29(1 Suppl 4):78-86
references.pmid: 11894017
references.citation: Methods Mol Biol. 2009;523:323-39
references.pmid: 19381928
references.citation: J Clin Invest. 2006 Aug;116(8):2208-2217
references.pmid: 16862215
references.citation: J Biol Chem. 2004 Oct 29;279(44):46343-9
references.pmid: 15328355
references.citation: Cell. 2010 Apr 2;141(1):52-67
references.pmid: 20371345
references.citation: Front Biosci. 1998 Apr 27;3:d447-8
references.pmid: 9556498
references.citation: Genome Res. 2006 Dec;16(12):1585-95
references.pmid: 17053090
references.citation: Drug News Perspect. 2008 Jul-Aug;21(6):331-5
references.pmid: 18836591
references.citation: J Biol Chem. 2002 Mar 22;277(12):10626-32
references.pmid: 11790795
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3890-5
references.pmid: 11904439
references.citation: Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):788-94
references.pmid: 20637913
references.citation: J Cell Biol. 2004 Nov 22;167(4):769-81
references.pmid: 15557125
references.citation: Nat Rev Cancer. 2002 Dec;2(12):910-7
references.pmid: 12459729
references.citation: Nature. 2009 Dec 17;462(7275):930-4
references.pmid: 20016602
references.citation: Oncogene. 2005 Apr 18;24(17):2796-809
references.pmid: 15838516
references.citation: Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
references.pmid: 17318226
references.citation: Int J Cancer. 2009 Jan 1;124(1):36-45
references.pmid: 18844224
references.citation: Cell Cycle. 2006 Aug;5(15):1597-601
references.pmid: 16880743
references.citation: Mol Cell Biol. 1998 Dec;18(12):7487-98
references.pmid: 9819434
references.citation: Cancer Res. 2010 Jun 15;70(12):4931-40
references.pmid: 20516113
references.citation: Mol Cancer Ther. 2010 Dec;9(12):3330-41
references.pmid: 21139044
references.citation: Nat Rev Cancer. 2011 Apr;11(4):289-301
references.pmid: 21430697
references.citation: Mol Cell Biol. 2010 Jan;30(2):524-36
references.pmid: 19917728
references.citation: Mol Cell Biol. 2001 Oct;21(20):6820-32
references.pmid: 11564866
references.citation: Nature. 2008 Aug 28;454(7208):1137-41
references.pmid: 18594513
references.citation: J Biol Chem. 2002 Nov 22;277(47):45154-61
references.pmid: 12192005
references.citation: Cell. 2004 Jan 23;116(2):235-46
references.pmid: 14744434
references.citation: Nat Rev Cancer. 2011 Jul 07;11(8):558-72
references.pmid: 21734724
references.citation: Oncogene. 2003 Mar 13;22(10):1445-60
references.pmid: 12629508
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5287-97
references.pmid: 19738110